Lumos Pharma to Participate in December Investor Conferences

AUSTIN, Texas, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ: LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to be held in December:

	Piper Sandler Healthcare Conference
	Date:	Monday, November 23, 2020
	What:	Fireside chat with Lumos Pharma management
	Management will host virtual one-on-one meetings during the conference on Wednesday, December 2, 2020. An on-demand download of the fireside chat is available as of November 23rd on the Piper Sandler conference portal and under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website.
	Evercore ISI HealthCONx
	Date:	Thursday, December 3, 2020
	Time:	1:00-1:45PM ET
	What:	Panel Discussion, “Easy Pills to Swallow: Oral Drugs for Large Endo Markets” – Chiasma, Crinetics, Lumos
	Management will host virtual one-on-one meetings throughout the day on Thursday, December 3, 2020. A live webcast of the panel discussion will be available on the company’s website under “Events & Presentations” in the Investors & Media section of Lumos Pharma’s website.

Please contact your Piper Sandler and Evercore ISI sales representatives to register for these investor conferences and to schedule a virtual one-on-one meeting with the Lumos Pharma management team.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding by leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Santé Ventures, and UCB. Lumos Pharma’s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit www.lumos-pharma.com.

Investor & Media Contact:

Lisa MillerLumos Pharma Investor Relations512-792-5454[email protected]

Source: Lumos Pharma, Inc.

Source: Lumos Pharma, Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• AB KN Energies holds a Webinar regarding unaudited financial results for the six months of 2026
• Equinor ASA: Announcement of cash dividend of NOK 3.6882 per share for first quarter 2026
• ALK appoints Jacob Glenting as head of Global R&D